Yazen doubles revenue and continues expansion in Europe

Yazen reported revenue of nearly €29.4m in 2025, up 87% from ~€15.7m, with gross profit roughly €16.5m (doubled year-over-year) while EBITDA was a negative €5.7m as the company ramped growth investments including >€17.8m in marketing. The digital obesity-care provider ended the year with over 37,000 active patients (39,000 in treatment as of January 2026), ARR of SEK 372m, presence in seven European markets and plans to enter two more in 2026 — indicating rapid top-line scale and market expansion that pressures near-term profitability but supports longer-term share gains.

Analysis

Market structure: Yazen’s 87% revenue growth and €17.8m marketing spend (≈61% of FY revenue) signals rapid demand creation for GLP‑1–class drugs and integrated digital care. Winners are large GLP‑1 manufacturers (Novo Nordisk NVO, Eli Lilly LLY) and scalable digital platforms able to leverage pharma supply; losers are single‑location clinics, low‑margin subscription diet services and incumbents unable to match medication+care bundles. Cross‑asset: expect positive equity re‑rating for NVO/LLY, modest widening of credit spreads for small private digital health players that may need capital, and limited FX effects except SEK funding pressure for Sweden‑based privates.

Risk assessment: key tail risks are (1) EU regulatory limits on remote prescribing of GLP‑1s, (2) global semaglutide/tirzepatide supply shocks, and (3) a capital‑markets stop that forces dilutive equity raises. Immediate risk (0–90 days) centers on funding runway given €5.7m negative EBITDA; medium term (3–12 months) is supply/reimbursement pressure as Yazen scales to two more countries in 2026; long term (12–36 months) is whether CAC payback falls under 24 months and marketing/Sales drops below ~30–40% to approach profitability. Hidden dependency: continued access to physician prescribers and wholesale drug supply agreements.

Trade implications: constructive for large pharma: establish 2–3% long positions in NVO and LLY with 6–12 month horizons; implement funded 6–12 month call spreads (buy ATM, sell 15–25% OTM) to cap cost. Underweight/short consumer telehealth/subscription names (HIMS, WW) by 1–2% of portfolio due to unsustainably high marketing ratios; deploy a pair trade long NVO / short TDOC (Teladoc) 1:1, 1% each, horizon 6–12 months. Rotate sector exposure toward big‑cap pharma and away from pure‑play telehealth/weight‑loss consumer stocks.

Contrarian angles: consensus overlooks that doubling revenue from a small base still leaves high absolute cash burn — marketing/Sales ~60% implies revenue must ~2×–3× to materially cut burn absent lower CAC or higher pricing. The market may underprice M&A as large pharma/pharmacy benefit managers seek distribution channels; conversely, overconfidence in scalability risks similar outcomes to US med‑spa/clinic rollups that re‑rated then collapsed when reimbursement and oversight tightened. Trade with strict liquidity and regulatory stop losses for 30–90 day windows.

Key Decisions for Investors

• Establish a 2–3% long position in Novo Nordisk (NVO) and a separate 2% long in Eli Lilly (LLY), horizon 6–12 months; hedge with 6–12 month call spreads (buy ATM, sell 15–25% OTM) to capture incremental GLP‑1 demand from digital providers.
• Reduce exposure by 50% to consumer telehealth/subscription weight‑loss names (example tickers: HIMS, WW) or initiate a 0.5–1% short basket across HIMS and WW, expecting margin compression as digital care providers scale marketing ahead of unit economics normalization.
• Initiate a 1% pair trade: long NVO, short TDOC (Teladoc) 1:1 weight, target 6–12 month holding period; exit if NVO underperforms pharma index by >8% or TDOC outperforms by >10% (cuts losses / take profits).
• Do not deploy capital into pure‑play European digital obesity providers until two conditions are met: (A) marketing/Sales declines below 40% or CAC payback <24 months, and (B) ARR > SEK 700m (~€60m). If a primary equity round is announced within 180 days, consider participating only at ≥20% discount to implied late‑stage private valuation.